What question did this study set out to answer?

The research aims to evaluate the prevalence of anemia and iron deficiency in cardiac amyloidosis and their impact on clinical outcomes.

February 8, 2026

Iron and the heart: understanding anemia in cardiac amyloidosis

Key Points

The research aims to evaluate the prevalence of anemia and iron deficiency in cardiac amyloidosis and their impact on clinical outcomes.
Enrolled patients with cardiac amyloidosis, including AL and ATTR subtypes.
Assessed clinical characteristics, medical history, laboratory data, and echocardiographic parameters.
Defined anemia and iron deficiency based on hemoglobin levels and transferrin saturation.
Used Kaplan-Meier analysis to examine associations between iron deficiency and clinical outcomes.
56.7% of cardiac amyloidosis patients had anemia, with higher prevalence in AL than ATTR.
Iron deficiency was found in 50.7% of the cohort, with significant associations noted with hemoglobin levels.
Transferrin saturation below 20% independently predicted adverse outcomes in both AL and ATTR subtypes.
Patients with iron deficiency had significantly higher NT-pro BNP levels at baseline, indicating increased risk.

Abstract

Abstract Introduction Anemia and iron deficiency (ID) are common comorbidities in patients with heart failure (HF) and have been associated with adverse clinical outcomes. However, their prevalence, clinical impact, and prognostic implications in cardiac amyloidosis (CA), particularly in transthyretin (ATTR) and light-chain (AL) subtypes, remain insufficiently explored. Given the frequent overlap between CA and HF, understanding the role of anemia and ID in CA is essential for optimizing patient management and identifying potential therapeutic targets. Aim We aimed to assess the prevalence of anemia and ID in CA subtypes and evaluate their association with clinical outcomes. Methods Patients with CA, including AL and ATTR types, were enrolled in a prospective registry. Clinical characteristics, medical history, laboratory and echocardiographic parameters were assessed at baseline. Anemia was defined as hemoglobin 13 g/dL in males and 12 g/dL in females, while ID was defined as transferrin saturation (TSAT) 20%. The primary endpoint was a composite of cardiac death and heart failure hospitalization. Results Anemia was present in 56.7% of CA patients, with higher prevalence in AL (69.6%) than ATTR (51.9%, p=0.007). ID was identified in 50.7% of the total cohort (AL: 43.0%, ATTR: 53.1%) (Figure 1). AL patients exhibited significantly lower hemoglobin levels than ATTR (AL: 12.3g/dL, ATTR: 13.4g/dL, p0.001), but within ATTR, ID was associated with reduced hemoglobin and hematocrit (p0.001 for both). TSAT 20% was independently predictive of adverse outcomes in both AL and ATTR subgroups (p0.001). In both CA subgroups, patients with ID had significantly higher levels of NT-pro BNP at baseline (3836.0pg/ml versus 2455.0pg/ml, p=0.010 in AL and 2972.0pg/ml versus 1656.0pg/ml, p=0.001 in ATTR). Kaplan-Meier analysis demonstrated an association between ID and increased risk of cardiac death or HF hospitalization, irrespective of left ventricular ejection fraction (LVEF) (Figure 2). Conclusion Anemia and ID are prevalent in patients with CA and are associated with worse clinical outcomes. A transferrin saturation (TSAT) level below 20% correlates with elevated NT-pro BNP levels, independently predicting poor outcomes in CA. These findings highlight the importance of screening for anemia and ID to identify patients at risk of adverse clinical outcomes. Additionally, they suggest that addressing ID may serve as a potential therapeutic target in both AL and ATTR subtypes of CA, warranting further investigation.Figure 1 Figure 2

Bookmark

Cite This Study

Schmid et al. (Sat,) studied this question.

synapsesocial.com/papers/6988292d0fc35cd7a88493fb https://doi.org/https://doi.org/10.1093/eurheartj/ehaf784.2739

Bookmark